Israel - inglés - Ministry of Health

astellas pharma international b.v., israel - tacrolimus - capsules - tacrolimus 0.5 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients. treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

maco pharma (uk) ltd - metronidazole - solution for infusion - 0.5 %w/v - imidazole derivatives

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

maco pharma (uk) ltd - sodium chloride ; glucose monohydrate - solution for infusion - %w/v - electrolytes with carbohydrates

Unión Europea - inglés - EMA (European Medicines Agency)

allergan pharmaceuticals international ltd - pancreas powder - exocrine pancreatic insufficiency - digestives, incl. enzymes - pancreatic enzyme replacement treatment in exocrine pancreatic insufficiency due to cystic fibrosis or other conditions (e.g. chronic pancreatitis, post pancreatectomy or pancreatic cancer).enzepi is indicated in infants, children, adolescents and adults.

Unión Europea - inglés - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - guanfacine hydrochloride - attention deficit disorder with hyperactivity - antiadrenergic agents, centrally acting, antihypertensives, - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. intuniv must be used as a part of a comprehensive adhd treatment programme, typically including psychological, educational and social measures.,

Australia - inglés - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - temozolomide, quantity: 140 mg - capsule, hard - excipient ingredients: indigo carmine; colloidal anhydrous silica; tartaric acid; gelatin; lactose; sodium starch glycollate; stearic acid; titanium dioxide; purified water; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - temozolomide, quantity: 250 mg - capsule, hard - excipient ingredients: purified water; tartaric acid; stearic acid; lactose; sodium starch glycollate; gelatin; colloidal anhydrous silica; titanium dioxide; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - temozolomide, quantity: 180 mg - capsule, hard - excipient ingredients: tartaric acid; stearic acid; lactose; iron oxide yellow; purified water; sodium starch glycollate; gelatin; titanium dioxide; iron oxide red; colloidal anhydrous silica; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - temozolomide, quantity: 100 mg - capsule, hard - excipient ingredients: gelatin; titanium dioxide; purified water; colloidal anhydrous silica; tartaric acid; sodium starch glycollate; stearic acid; iron oxide red; lactose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - temozolomide, quantity: 20 mg - capsule, hard - excipient ingredients: lactose; iron oxide yellow; tartaric acid; stearic acid; titanium dioxide; gelatin; colloidal anhydrous silica; purified water; sodium starch glycollate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.